GnRH agonist treatment for males with locoregional prostate cancer was linked to an elevated risk of diabetes and cardiovascular disease (CAD, MI, and SCD), according to Keating et al. (2006) [23]. ADT with GnRH agonists was linked to an elevated risk of diabetes and CVD (CAD, MI, and SCD), ADT with CAB was linked to an enhanced risk of CAD, ADT with orchiectomy was linked to CAD and MI, and oral anti-androgen monotherapy was not linked to any of the outcomes studied, according to Keating (2010) [24]. The gene discussed is GNRH1; the disease is prostate cancer.